Hormonal
Tirzepatide treatment significantly reduces the 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) in adults with obesity or overweight without diabetes compared to placebo.
If you have obesity or overweight without diabetes, treatment with tirzepatide (a once-weekly injection) combined with lifestyle changes can significantly lower your calculated 10-year risk of heart disease compared to placebo. This benefit was observed across different baseline risk levels, suggesting it may be a valuable option for long-term cardiovascular health improvement in this population.
Tirzepatide treatment significantly reduced the 10-year predicted risk of ASCVD versus placebo in patients with obesity or overweight without diabetes.
Why this rating
Based on a large phase 3 trial (SURMOUNT-1) with rigorous statistical analysis (MMRM), though it is a post hoc analysis of predicted risk rather than hard clinical events.
Source
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT‐1 post hoc analysis
Emily R. Hankosky et al. · Diabetes Obesity and Metabolism · 2023
DOI 10.1111/dom.15318
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →